ATE498016T1 - Transposon-system zur gezielten integration - Google Patents

Transposon-system zur gezielten integration

Info

Publication number
ATE498016T1
ATE498016T1 AT04709603T AT04709603T ATE498016T1 AT E498016 T1 ATE498016 T1 AT E498016T1 AT 04709603 T AT04709603 T AT 04709603T AT 04709603 T AT04709603 T AT 04709603T AT E498016 T1 ATE498016 T1 AT E498016T1
Authority
AT
Austria
Prior art keywords
poly
domain
transposase
peptide
targeted integration
Prior art date
Application number
AT04709603T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Original Assignee
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum filed Critical Max Delbrueck Centrum
Application granted granted Critical
Publication of ATE498016T1 publication Critical patent/ATE498016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04709603T 2003-02-10 2004-02-10 Transposon-system zur gezielten integration ATE498016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002637 2003-02-10
PCT/EP2004/001220 WO2004069994A2 (en) 2003-02-10 2004-02-10 Transposon-based targeting system

Publications (1)

Publication Number Publication Date
ATE498016T1 true ATE498016T1 (de) 2011-02-15

Family

ID=32842694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709603T ATE498016T1 (de) 2003-02-10 2004-02-10 Transposon-system zur gezielten integration

Country Status (7)

Country Link
US (1) US20080008687A1 (de)
EP (1) EP1594972B1 (de)
JP (1) JP2006518203A (de)
AT (1) ATE498016T1 (de)
DE (1) DE602004031325D1 (de)
DK (1) DK1594972T3 (de)
WO (1) WO2004069994A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067402A1 (de) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transposon-vermittelte Mutagenese in Spermatogoniestammzellen
US8735156B2 (en) 2008-12-01 2014-05-27 The Board Of Regents Of The University Of Texas System Production and use of rat spermatogonial stem cell lines
US10689643B2 (en) 2011-11-22 2020-06-23 Active Motif, Inc. Targeted transposition for use in epigenetic studies
EP2740353A1 (de) 2012-12-06 2014-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige induzierbare Tiermodelle für Stressverhalten
WO2014143383A1 (en) * 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
JP7275043B2 (ja) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
CN112543808A (zh) 2018-06-21 2021-03-23 比莫根生物科技公司 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法
CA3113435A1 (en) * 2018-09-25 2020-04-02 Emory University Nucleic acids for cell recognition and integration
AU2019429609B2 (en) 2019-02-13 2025-09-25 Probiogen Ag Transposase with enhanced insertion site selection properties
CN110776570A (zh) * 2019-10-22 2020-02-11 上海海洋大学 一种重组转座酶及其用途
KR20230038425A (ko) 2020-07-17 2023-03-20 프로바이오겐 아게 과활성 트랜스포손 및 트랜스포사제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027643A1 (en) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
DE69841648D1 (de) * 1997-03-11 2010-06-17 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
US5958775A (en) * 1997-07-25 1999-09-28 Thomas Jefferson University Composition and method for targeted integration into cells
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
EP1303608A2 (de) * 2000-07-21 2003-04-23 Syngenta Participations AG Code zur erkennung von zinkfingerdomänen und dessen verwendungen
DE60335637D1 (de) * 2002-07-24 2011-02-17 Manoa Biosciences Inc Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren

Also Published As

Publication number Publication date
EP1594972A2 (de) 2005-11-16
WO2004069994A3 (en) 2004-10-28
JP2006518203A (ja) 2006-08-10
WO2004069994A2 (en) 2004-08-19
EP1594972B1 (de) 2011-02-09
DK1594972T3 (da) 2011-04-18
DE602004031325D1 (de) 2011-03-24
US20080008687A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ATE536419T1 (de) Transposon basiertes targeting- system
ATE497540T1 (de) Transposon-system zur gezielten integration
ATE498016T1 (de) Transposon-system zur gezielten integration
WO2007140505A3 (en) Vaccine carrier
SG162687A1 (en) Caustic stable chromatography ligands
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
NI200900097A (es) FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLÓGICA MEJORADA.
WO2007081851A3 (en) Affinity chromatography matrices and methods of making and using the same
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2007031280A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
NZ598770A (en) Monoclonal antibodies
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
MX358705B (es) Agentes de union de esclerostina.
WO2009081285A3 (en) Hepatitis c virus antibodies
AU2009260320A8 (en) Antibodies to IL-6 and their uses
BRPI0411854A (pt) veìculos protéicos para vacinas
WO2007115571A8 (en) Erbb receptor-derived peptide fragments
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DE602005009827D1 (de) Verfahren zur aufreinigung von il-18-bindendem protein
WO2006132739A3 (en) Novel chemical compounds
EA200800570A1 (ru) Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
WO2009108949A3 (en) Cold shock protein compositions and methods and kits for the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties